RICT 2010 - Interfacing Chemical Biology and Drug Discovery
Reims, France - June 30 - July 2, 2010
We have the pleasure to invite you to register for the upcoming edition of RICT 2010, the annual 3 days symposium of the Société de
Chimie Thérapeutique (SCT), which will be held at the Faculty of Pharmacy in Reims under the title: Interfacing Chemical Biology and Drug
Discovery.
Dr Luc Van Hijfte, Research Director Janssen-Cilag and Head Medicinal Chemistry Europe Johnson & Johnson Pharmaceutical
R&D has made us the pleasure to share his thoughts on the subject of the symposium. For him, when looking back how drugs were
discovered in the mid to late nineties, it becomes apparent that the role of chemists in this endeavor has dramatically changed. Where the
role of the chemist mainly was to synthesize small organic molecules, aiming to optimize biological activity, it is clear that his role today
goes largely beyond optimizing for primary biological activity.
Today, it is expected from the chemists to be multidisciplinary experts in the fields of biology, ADME-T, computer assisted drug design,
the use of various IT systems allowing to extract and visualize the data, patent space and law…, in order to be able to orchestrate the
optimization of hit molecules to NMEs in a multi-factorial fashion. In addition, he is also expected to provide his organic chemistry skills to
design tool compounds, imaging agents, PET ligands, solutions for diagnostic tools, etc …, enabling the biologists in the unravelling and
understanding of the extremely complex biological systems. Finally, he is supposed to be able to propose alternative drug delivery
technologies and/or prodrugs for improved systemic exposures. In summary, from being an expert in pure medicinal chemistry, the
chemist’s role has now evolved to being an expert in chemical biology.
Since a number of years, the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique – SCT) has paid full attention to this
evolution, and this year again, the 46th International Conference on Medicinal Chemistry (RICT 2010) aims to bring together people
concerned by the multiple aspects of Chemical Biology and Drug Discovery.
For more details about the symposium, registration and hotel booking, we invite you to visit the website: www.medchem.fr
You can also download the poster which can be used for print-outs and for announcing the symposium in your institution.
Hoping to get the opportunity to meet you in Reims in July.
With our best regards
Professor Janos Sapi
UNIVERSITY OF REIMS CHAMPAGNEARDENNE
Chairman of Local Organising Committee
Professor André Tartar
UNIVERSITY OF LILLE
President of the SCT (Société de Chimie
Thérapeutique)
CALL FOR ABSTRACTS
A poster session will provide the opportunity for all participants to present their current results. All participants are invited to submit abstracts
of scientific communications which will be peer-reviewed for their acceptance. The abstracts of the accepted communications will be
published in the book of abstracts which is distributed to all Symposium attendants. A “best poster” prize will also be attributed.
Deadline for abstract submission: May 25, 2010
PROGRAMME
- Discovery of Inhibitors of MAPKAPK5, a Novel Target for Rheumatoid Arthritis
Dr Martin ANDREWS (GALAPAGOS NV, Mechelen, Belgium)
- Topically Bioavailable and Systemically Safe PPARgamma Agonists as Sebum Modulators
Dr Jean-Guy BOITEAU (GALDERMA R&D, Sophia-Antipolis, France)
- Pyrrolopyrimidine-Based P2X3 Antagonists for the Treatment of Pain
Dr Louis-David CANTIN (ASTRAZENECA R&D, Montréal, Canada)
- New Methods for Peptide Synthesis
Prof. David CRICH (ICSN, Gif-sur-Yvette, France)
- Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target
Dr Max CUMMINGS (TIBOTEC, Mechelen, Belgium)
- Sugars and Proteins
Prof. Ben DAVIS (OXFORD UNIVERSITY, Oxford, United Kingdom)
- Hybrids: Natural Products with Neurotrophin Activity
Dr Bruno FIGADERE (UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France)
- Telbivudine, a Potent and Specific Anti-HBV Nucleoside Analogue: From the Bench to its Marketing Approvals (Tyzeka®, Sebivo®)
Dr Gilles GOSSELIN (IDENIX SARL, Montpellier, France)
- Peptidomimetic Foldamers: Connecting Structure to Function
Dr Gilles GUICHARD (IECB, Bordeaux, France)
- The First NO- and Heam-independent Activator of Soluble Guanylate Cyclase for the IV Treatment of Acute Heart Failure
Dr Michael G. HAHN (BAYER HEALTHCARE, Wuppertal, Germany)
- Two Stimulating Concepts in Natural Substances Synthesis: the NEO Cascade and the CIM Strategy
Prof. Arnaud HAUDRECHY (UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, Reims, France)
- Identification of Functionally Selective Alpha2C-AR Agonists as Potential New Drugs for Treatment of Pain
Dr Eric JNOFF (UCB PHARMA SA, Braine-l'Alleud, Belgium)
- Virtual Screening in Drug Discovery: Overview and Applications
Dr Romano KROEMER (SANOFI AVENTIS, Vitry sur Seine, France)
- Inhibitors of PKC-beta and GSK-3beta: A Tale of Two Kinases
Dr Bruce MARYANOFF (SCRIPPS, San Diego, United States)
- Active Pharmaceutical Ingredients in Convergent Technologies: How Are They Chosen
Dr Cynthia MARYANOFF (CORDIS, A JOHNSON AND JOHNSON COMPANY, Spring House, United States)
- Fragment-based Design of Small RNA Binders
Dr Laurent MICOUIN (UNIVERSITÉ DE PARIS DESCARTES, Paris, France)
- A Single Synthetic Peptide for Immunomodulating Lupus, a Complex Autoimmune Disease
Dr Sylviane MULLER (IBMC-CNRS, Strasbourg, France)
- Prodrug Approaches for Enhancing the Bioavailability of Drugs
Prof. Christa MÜLLER (UNIVERSITY OF BONN, Bonn, Germany)
- Vascular Tumor Targeting
Prof. Dario NERI (ETH-ZÜRICH, Zürich, Switzerland)
- Functional Assays as Multifaceted Tools for HTS
Dr Olivier NOSJEAN (SERVIER RESEARCH INSTITUTE, Croissy-sur-Seine, France)
- The Identification of Selective p38 MAPK Inhibitors with High Blood Potency Suitable for Clinical Development: The Discovery of
Losmapimod
Dr Vipul K. PATEL (GLAXOSMITHKLINE, Stevenage, United Kingdom)
- Novel Antagonists of Protease Activated Receptors 1: Unusual GPCRs Implicated in Cardiovascular Diseases
Dr Michel PEREZ (INSTITUT DE RECHERCHE PIERRE FABRE, Castres, France)
- Indole-carboxylic Acid Amides as Novel CETP Inhibitors: From Hit to Clinical Candidate and Beyond
Dr Philippe PFLIEGER (F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- Carbonic Anhydrases: Novel Therapeutic Applications for Inhibitors and Activators
Prof. Claudiu SUPURAN (UNIVERSITY OF FIRENZE, Sesto Fiorentino, Italy)
- Novel Compound Classes as Calcilytics for the Treatment of Osteoporosis
Dr Leo WIDLER (NOVARTIS, Basel, Switzerland)
Symposium Secretariat
LD ORGANISATION
Tel : +32 10 45 47 77
Fax : +32 10 45 97 19
E-mail : secretariat@LDOrganisation.com
Url : http://www.LDOrganisation.com